Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics
Olympus to take a significant equity stake in Swan EndoSurgical with a combined initial investment of at least $65 million.Swan EndoSurgical to develop an innovative endoluminal robotic system for less invasive therapeutic treatments.The total combined funding could reach up to $458 million if pre-agreed milestones are met and the program reaches term.TOKYO, July 25, 2025 – (JCN Newswire via SeaPRwire.com) – Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer, and more fulfilling, today announced the conclusion of an agreement with Revival Healthcare Capital (Revival) to drive advancements in endoluminal robotics. Olympus and Revival will co-found Swan EndoSurgical, a new company dedicated to developing a novel robotic system designed to revolutionize gastrointestinal (GI) patient care in the future.Logo of Swan EndoSurgicalEndoluminal robotics aims to empower more physicians to safely perform innovative techniques, enhancing patient access to treatment …